Population Pharmacokinetics of Caspofungin in Candidiasis Patients.

J.A. STONE, S. LI, G. WINCHELL, S. BI, P. WICKERSHAM, M. SCHWARTZ, N. KARTSONIS, C. SABLE

Author address: 

Merck Research Labs., West Point, PA.

Abstract: 

Background: Caspofungin (Cancidas™) is an echinocandin antifungal agent. Methods: End-of-infusion (C1hr) and trough (C24hr) concentrations were obtained in 222 localized (esophageal and oropharyngeal) candidiasis patients (LC) receiving 35, 50, or 70 mg IV once daily caspofungin and in 91 invasive candidiasis (IC) patients receiving 50 mg once daily with a 70 mg loading dose on Day 1. AUC(0-24hr) was obtained in a subset of LC patients (n=105). The potential for covariates (age, gender, weight, race, renal status, serum albumin level, HIV status, and CD4 cell count) to predict log-transformed PK was evaluated using a multiple linear regression model constructed after an initial screen and refined by step-wise (backward) regression. In a separate analysis, univariate drug interaction screens compared PK in patients receiving a concomitant medication (>90% of therapy) to PK in patients never receiving that medication. Results: In the covariate analyses, weight, gender, and albumin level were statistically significant (p
2003

abstract No: 

A-1571

Full conference title: 

43rd Interscience Conference on Antimicrobial Agents
    • ICAAC 43rd